Evidence map›Paper›PMID 35361992›Full record

ArticleNature medicine2022

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Ben Killingley, Alex J Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie Zhou, Kate Lindsell, Samanjit S Hare, Jonathan Brown, Rebecca Frise and 21 more

Registry-linked trialOpen access · bronzeAbstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06654973 (The Singapore Platform for Controlled Human Infections With SARS-CoV-2), which is not on this map. Cited by 293 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed, 6 pooled it
49.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06654973 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

The Singapore Platform for Controlled Human Infections With SARS-CoV-2

TypeinterventionalSponsorTan Tock Seng HospitalRan2024 to 2026Enrolled20ConditionsCOVID 19ArmsGMP-produced SARS-CoV-2 Delta strain
3 · Its place in the literature

Who cites it

293 citing papers in PubMed, 6 syntheses or guidelines pooled it, 516 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Virus-Mediated Self-Assembly of Functional Cyclodextrins for Antiviral Inhibition.Angewandte Chemie (International ed. in English) · 2026
    Article
  19. Article
  20. Article

233 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 11 institutions in 1 country.

Ben Killingley *Department of Infectious Diseases, University College London Hospital, London, UK.
Alex J Mann *hVIVO Services Ltd., London, UK.ORCID http://orcid.org/0000-0002-3744-4604
Mariya KalinovahVIVO Services Ltd., London, UK.
Alison BoyershVIVO Services Ltd., London, UK.
Niluka GoonawardaneDepartment of Infectious Disease, Imperial College London, London, UK.
Jie ZhouDepartment of Infectious Disease, Imperial College London, London, UK.
Kate LindsellUK Vaccine Taskforce, Department for Business, Energy and Industrial Strategy, London, UK.
Samanjit S HareDepartment of Radiology, Royal Free London NHS Foundation Trust, London, UK.
Jonathan BrownDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-6849-3962
Rebecca FriseDepartment of Infectious Disease, Imperial College London, London, UK.
Emma SmithNational Heart and Lung Institute, Imperial College London, London, UK.
Claire HopkinsENT Department, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Nicolas NoulinhVIVO Services Ltd., London, UK.
Brandon LöndthVIVO Services Ltd., London, UK.
Tom WilkinsonFaculty of Medicine and Institute for Life Sciences, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
Stephen HardenDepartment of Radiology, Southampton General Hospital, Southampton, UK.
Helen McShaneDepartment of Paediatrics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2126-5142
Mark BailletS-cubed Biometrics, Abingdon, UK.
Anthony GilbertUK Vaccine Taskforce, Department for Business, Energy and Industrial Strategy, London, UK.
Michael JacobsDepartment of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.
Christine CharmanUK Vaccine Taskforce, Department for Business, Energy and Industrial Strategy, London, UK.
Priya MandeUK Vaccine Taskforce, Department for Business, Energy and Industrial Strategy, London, UK.
Jonathan S Nguyen-Van-TamDivision of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK.
Malcolm G SempleHealth Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool; Respiratory Department, Alder Hey Children's Hospital, Liverpool, UK.ORCID http://orcid.org/0000-0001-9700-0418
Robert C ReadFaculty of Medicine and Institute for Life Sciences, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.ORCID http://orcid.org/0000-0002-4297-6728
Neil M FergusonMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-1154-8093
Peter J OpenshawNational Heart and Lung Institute, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-7220-2555
Garth RapeportNational Heart and Lung Institute, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-5795-6500
Wendy S BarclayDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-3948-0895
Andrew P CatchpolehVIVO Services Ltd., London, UK.
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, UK. c.chiu@imperial.ac.uk.ORCID http://orcid.org/0000-0003-0914-920X
Imperial College London · GBhVIVO (United Kingdom) · GBDepartment for Business, Energy and Industrial Strategy · GBRoyal Free London NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBSouthampton General Hospital · GBUniversity College Hospital · GBUniversity of Liverpool · GBUniversity of Nottingham · GBUniversity of Oxford · GB

Funding

Cancer Research UK C18616/A25153Department of Health 200907Department of Health 200927Department of Health CO-CIN-01Department of Health IS-BRC-1215-20004Department of Health NF-SI-0617-10010Department of Health NIHR201385Department of Health NIHR-BRC-1215-20008Medical Research Council MC_PC_19025Medical Research Council MC_PC_19059Medical Research Council MR/R015600/1Medical Research Council MR/V028448/1
6 · The paper itself

Abstract

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of cases and continues to circulate globally. To establish a novel SARS-CoV-2 human challenge model that enables controlled investigation of pathogenesis, correlates of protection and efficacy testing of forthcoming interventions, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansKineticsTreatment OutcomeViral LoadYoung AdultAntibodies, Viral

Identifiers

PMID35361992
OpenAlexW4221135099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.